Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8538844 | 1.00 | DRD2 (0.65) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL357358 | 1.00 | DRD2 (0.65) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL1626963 | 1.00 | DRD2 (0.65) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL28148490 | 0.98 | DRD2 (0.63) | DRD2DRD3HTR1AHTR2A | |
| Ammonia Solution, Strong SCHEMBL27880976 | 0.98 | DRD2 (0.63) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL319782 | 0.98 | DRD2 (0.63) | DRD2DRD3HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL1711121 | 0.98 | DRD2 (0.63) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL28845061 | 0.98 | DRD2 (0.63) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL27453341 | 0.90 | DRD2 (0.59) | DRD2DRD3 | |
| SCHEMBL19866138 | 0.89 | DRD2 (0.53) | DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1049431-C | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 2000-02-16 | — | — | CN | claimed |
| CN-1147254-A | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | claimed |
| CN-122011029-A | Ternary condensed ring compound and application thereof in medicine | 杭州百新生物医药科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4126853-B1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | SCRIPPS RESEARCH INST (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | REGENTS OF THE UNIV OF MICHICAN (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | UNIV MICHIGAN (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | REGENTS OF THE UNIV OF MICHICAN (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | UNIV MICHIGAN (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| WO-2023078392-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20030215456-A1 | Method of treating cancer | YAO SUI-LONG (US) | 2003-11-20 | — | — | US | disclosed |
| CN-1075812-C | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 2001-12-05 | — | — | CN | disclosed |
| CN-1049431-C | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 2000-02-16 | — | — | CN | disclosed |
| CN-1147254-A | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | disclosed |
| EP-0748320-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| EP-0734381-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5512570-A | Treatment of emesis with morpholine tachykinin receptor antagonists | MERCK & CO., INC. (US) | 1996-04-30 | — | — | US | disclosed |
| WO-1995023798-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | DRD2 3660/4885DRD3 3465/4885HTR1A 1769/4885 |
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | STAT6, STAT5B, STAT5A | DRD2 3804/4885DRD3 3963/4885HTR1A 3532/4885 |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | DRD2 604/4885DRD3 442/4885HTR1A 107/4885 |
| US-20030215456-A1 | Method of treating cancer | TACR1, TACR2, KLK3 | DRD2 3006/4885DRD3 3802/4885HTR1A 328/4885 |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | STAT6, STAT5B, STAT5A | DRD2 4390/4885DRD3 4370/4885HTR1A 3939/4885 |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | DRD2 4853/4885DRD3 4791/4885HTR1A 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.